Bright Uro Inc. raised $23 million in a series A fundraising round to support its pursuit of U.S. FDA 510(k) clearance and launch of its Glean urodynamics system. Glean offers catheter-less assessment of the function of the bladder and urethra that uses an inserted pressure sensor instead.